Pharmacy Innovations: Drug Recall

Recall #D-0196-2023 · 12/22/2022

Class II: Risk

Recall Details

Recall Number: D-0196-2023
Classification: Class II
Product Type: Drug
Recalling Firm: Pharmacy Innovations
Status: Terminated
Date Initiated: 12/22/2022
Location: Erie, PA, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: N/A

Reason for Recall

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Product Description

Buprenorphine HCL 0.9 MG/ML (25ML vial) Injectable, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.

Distribution Pattern

Nationwide in the USA

Other Recalls by Pharmacy Innovations

Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

View all recalls by Pharmacy Innovations →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.